JLL Partners related stories
All articles and analysis
Odyssey Fund IV performance climbs on recent exitsOdyssey Investment Partners faced the worst economic downturn since the Great Depression when it launched fundraising for Odyssey Investment Partners IV in 2008. But the New York firm led by Chairman Stephen Berger, a leader in the New York political arena, barely missed a beat.
JLL Partners raise $254m for seventh fundThe New York-based middle market firm is targeting $1 billion for its latest fund
Talking Top Quartile with Paul Levy, Managing Director, JLL PartnersJLL Partners Fund VI LP turned in an IRR of 19.3 percent, above the top quartile threshold of 19.0 percent and the median of 10.6 percent for the crop of 2008 funds, according to an analysis of pension fund data in the Sept. 2, 2013, issue of Buyouts. Paul Levy, managing director, who founded the firm in 1988 after working at Drexel Burnham Lambert, spoke by phone from his firm’s New York office.
JLL Fund VII eyes $500 mln first closeJLL Partners expects to hold a $500 million first close for its seventh fund later this summer, peHUB has learned.
U.S. sponsors finding ways to get money to workU.S. sponsors rang up the most robust first-quarter deal count since 2007
- Talking Price Point with Steve Gelsi: Thoma Bravo's aggressive 15.5x multiple for TravelClick may pay off
With a total deal price of $930 million and a trailing 12-month EBITDA of $60 million, Thoma Bravo is betting that its aggressive 15.5x purchase price multiple for the pending acquisition of Genstar Capital’s TravelClick business will lead to more growth ahead.
- Water Street and JLL Partners completes merger of CCBR-SYNARC and BioClinica
Water Street Healthcare Partners and JLL Partners said Wednesday that they have completed the merger of CCBR-SYNARC and BioClinica. No financial terms were disclosed. Both Water Street and JLL Partners have named Jeffrey McMullen to serve as chairman of the combined company, which will provide specialty outsourced clinical services.
- JLL Partners and Royal DSM complete Dpx Holdings transaction
JLL Partners and Royal DSM, a global life sciences and materials sciences company have closed the transaction announced in November 2013 combining DSM Pharmaceutical Products and Patheon Inc into a new privately held company named DPx Holdings. With headquarters in Durham, N.C., DPX’s global footprint includes 24 global locations across North America, Europe, Latin America and Australia.
Patheon take-private deal closed, company forms part of JLL-controlled DPxPatheon Inc (TSX:PTI), a provider of drug development and manufacturing services, has completed the previously announced deal to take the company private. That transaction, which valued company at US$1.4 billion, will result in Patheon being amalgamated with JLL/Delta Canada Inc, an indirect subsidiary of DPx, formed http://www.reuters.com/article/2014/03/11/ny-jll-partner-royal-dsm-idUSnBw116434a+100+BSW20140311 by U.S. private equity firm JLL Partners and Dutch food and chemicals group Royal DSM in a separate US$2.65 billion deal. Patheon will continue to carry on business under its own name. At the time of the Patheon deal announcement /canada/2013/11/19/patheon-taken-private-jll-partners-dsm-1-4-bln/ in November 2013, the proposed offer of US$9.32 per share implied a US$582 million payout to investors other than JLL, which has had a major stake in Patheon since 2007. DPx, which is based in Durham, North Carolina, is 51% owned by JLL and 49% by Royal DSM. Patheon was found in Fort Erie, Ontario, in 1974.
- Atlantic-Pacific hires Credit Suisse managing director(2)
Atlantic-Pacific Capital has added Brian Wade as a partner to work with institutional investors in the mid-Atlantic and Southeast United States.